References
- Jackson K, Ashby M, Howell D, et al. The effectiveness and adverse effects profile of “burst” ketamine in refractory cancer pain: the VCOG PM 1-00 study. J Palliat Care. 2010;26:176–183.
- National Comprehensive Cancer Network (NCCN). Adult Cancer Pain (version 2.2015). http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed July 12, 2015.
- Prommer EE. Ketamine for pain: an update of uses in palliative care. J Palliat Med. 2012;15:474–483.
- Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30:3611–3617.
- Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. “Burst” ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage. 2001;22:834–842.
- Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage. 2003;25:302–305.
- Quibell R, Fallon M, Mihalyo M, Twycross R, Wilcock A. Ketamine. J Pain Symptom Manage. 2015;50(2):268–78.
- Tam SW, Zhang A. Sigma and PCP receptors in human frontal cortex membranes. Eur J Pharmacol. 1998;154:343–344.
- Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223:5–8.
- American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th ed. Glenville, IL: American Pain Society; 2008:19–21.